SEC EDGARAUG 32 min read$CTNM

Stengone Carmine N. sold $40K of CTNM

Stengone Carmine N. (CEO and President) sold 2,500 shares of Contineum Therapeutics, Inc. (CTNM) at $16.01 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Stengone Carmine N.

Published Aug 3, 2026, 10:14 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 3, 2026, 10:16 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CTNM

Neutral

high confidence

Mentioned

$CTNM

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CTNMNeutralLow

Why it matters

The newest disclosed fact is the CEO’s open-market sale of 2,500 shares at $16.0116 under a pre-arranged 10b5-1 plan.

Market read

Primarily a routine insider-sale datapoint; limited standalone trading signal due to 10b5-1 pre-arrangement.

What to watch

Traders may want to compare this sale size and frequency to prior Form 4 activity and the company’s recent news flow, which is not provided here.

Relevance 2/10Novelty 3/10Timing: today’s SEC Form 4 filing (2026-08-03)

Background

The article is an SEC Form 4 insider transaction disclosure for Contineum Therapeutics, Inc. (CTNM).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CTNMNeutralHigh confidence

Context

Contineum Therapeutics CEO and President Stengone Carmine N. sold 2,500 shares on 2026-08-03 at $16.0116, per Form 4.

Expected impact

Low near-term impact; any reaction is likely muted unless traders suspect plan timing or unusual size versus prior activity.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan, reducing interpretive weight for directional forecasting.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can still coincide with internal liquidity needs or diversification, so it may not reflect bearish fundamentals.

Key entities

issuer
Contineum Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
insider
Stengone Carmine N.
CEO and President who executed the reported sale.

Read at source ← All news

SEP 25

$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min

SEP 24

$CTNMMed

Goldman Sachs initiates coverage on Contineum Therapeutics stock

Goldman Sachs initiated coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Early-Stage Biotech rating. The stock trades at $12.51, down 5.3% in a week. The company is developing oral therapies for inflammatory and fibrotic conditions. Its lead candidate, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. Despite a recent trial failure, Stifel maintains a Buy rating with a $28 price target.

investing.com2 min

SEP 15

$CTNMMedAI 8/10

Contineum Therapeutics Tumbles After Depression Drug Misses Primary Goal in Phase 2 — BigGo Finance

Contineum Therapeutics (CTNM) shares fell in after-hours trading after its depression drug candidate, licensed to Johnson & Johnson (JNJ), missed the primary efficacy endpoint in a Phase 2 trial. This is the second Phase 2 failure for the same molecule in less than a year. The company's focus shifts to its lung-disease program, PIPE-791. JNJ is evaluating the trial data, but no decision on further development has been made. Contineum shares declined 3.5% to $14.30 in after-hours trading, while J

finance.biggo.com2 min

SEP 15

$CTNMMed

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics (CTNM) shares fell 9.58% after its Phase 2 MOONLIGHT-1 trial for depression drug JNJ-5120/PIPE-307, developed with Johnson & Johnson (JNJ), missed its primary efficacy endpoint. JNJ is reviewing data to determine next steps. CTNM's stock is near key support at $13.60 and resistance at $15.34.

aol.com2 min

SEP 14

$CTNMHighAI 8/10

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?

Contineum Therapeutics (CTNM) shares fell 10% after-hours after J&J's (JNJ) mid-stage trial of PIPE-307, licensed from CTNM, failed to meet its primary goal in treating major depressive disorder. This is the second mid-stage setback for the molecule in under a year. JNJ is reviewing exploratory measures and has not decided on further development. CTNM has $236.6 million in cash, expected to last through mid-2029.

newsable.asianetnews.com2 min